Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bazedoxifene, Bazedoxifene Acetate, Bazedoxifene Acetate (TSE-424)
Bazedoxifene and conjugated estrogens · 14 trials · 7 indications
Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. If both the pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted. Results were summarized for two definitions of hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia); definition 1: participants were considered to have a diagnosis of hyperplasia when the 3 pathologists disagreed but at least 1 pathologist determined hyperplasia; definition 2: participants were considered to have a diagnosis of hyperplasia if at least 2 of the 3 pathologists agreed on the diagnosis.
BMD measurements of the anteroposterior lumbar spine were acquired by using dual-energy x-ray absorptiometry (DXA) scans, twice at Month 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.
Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.
Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.
BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.
BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.
BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.
BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.
New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | bazedoxifene 20 mg/conjugated estrogens 0.45 mg |
| 2 | EXPERIMENTAL | bazedoxifene 20 mg/conjugated estrogens 0.625 mg |
| 3 | EXPERIMENTAL | bazedoxifene 20 mg |
| 4 | ACTIVE_COMPARATOR | Prempro |
| 5 | PLACEBO_COMPARATOR | Placebo |
| Arm 2 | EXPERIMENTAL | BZA 20mg/CE 0.45 |
| Arm 3 | ACTIVE_COMPARATOR | CE 0.45mg/MPA1.5mg |
| Arm 4 | PLACEBO_COMPARATOR | Placebo |
| A | EXPERIMENTAL | - |
| B | ACTIVE_COMPARATOR | - |
| C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| bazedoxifene 20 mg/ conjugated estrogens 0.45 mg | DRUG | One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year. |
| bazedoxifene 20 mg/ conjugated estrogens 0.625 mg | DRUG | One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year. |
| bazedoxifene 20 mg | DRUG | One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year. |
| conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg | DRUG | One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year. |
| Placebo | DRUG | One capsule, placebo (over-encapsulated), once a day for one year. |
| Bazedoxifene/Conjugated Estrogen | DRUG | - |
| CE 0.45 mg/MPA 1.5mg | DRUG | Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study. |
| Bazedoxifene/Conjugate Estrogens (CE) | DRUG | - |
| Raloxifene | DRUG | - |
| Bazedoxifene Acetate | DRUG | BZA 20mg, daily, oral |
| Bazedoxifene Acetate (TSE-424) | DRUG | - |
| Bazedoxifene | DRUG | - |
| Bazedoxifene and conjugated estrogens | DRUG | Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart. |
| Bazedoxifene/Conjugated Estrogens | DEVICE | - |
| Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet | DRUG | - |
| bazedoxifene/conjugated estrogens combination tablet | DRUG | - |
Inclusion Criteria: * Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms * At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL * Intact Uterus Exclusion Criteria: ...
Bazedoxifene and conjugated estrogens is a small molecule combination therapy developed by Pfizer (PFE) for postmenopausal women. It pairs bazedoxifene acetate with conjugated estrogens and has been studied in Phase 3 trials for menopause, osteoporosis, endometrial hyperplasia, and vaginal atrophy.
Bazedoxifene and conjugated estrogens is used for conditions affecting postmenopausal women, including menopause, postmenopausal osteoporosis, osteoporosis, endometrial hyperplasia, and vaginal atrophy. It is a combination tablet containing bazedoxifene acetate and conjugated estrogens.
Bazedoxifene and conjugated estrogens targets the estrogen receptors ESR1 and ESR2. Bazedoxifene acts as a modulator of these receptors, while the conjugated estrogens component provides estrogenic activity, together forming a combined estrogen and selective estrogen receptor modulator approach.
Bazedoxifene and conjugated estrogens is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company behind the bazedoxifene/conjugated estrogens combination tablet.
Bazedoxifene and conjugated estrogens is in Phase 3 development. Four clinical trials have been completed, including Phase 3 and Phase 1 studies, with no active trials currently ongoing. It is an investigational combination therapy.
Bazedoxifene and conjugated estrogens has been evaluated in completed trials including NCT00808132, a Phase 3 study of endometrial safety and postmenopausal osteoporosis; NCT00675688, a Phase 3 safety and efficacy study; NCT00706225, a Phase 1 drug interaction study; and NCT00550433, a Phase 1 study in postmenopausal women.
No, bazedoxifene and conjugated estrogens is a combination product containing both bazedoxifene acetate and conjugated estrogens. Bazedoxifene alone is a separate component. The combination is also known as bazedoxifene/conjugated estrogens combination tablet and bazedoxifene 20 mg/conjugated estrogens 0.45 mg.